Who are Cilostazol+Probucol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cilostazol + Probucol group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cilostazol-probucol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Cilostazol+Probucol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cilostazol+Probucol (Cilostazol+Probucol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent + Antioxidant lipid-lowering agent. Area: Cardiovascular.

marketed Antiplatelet agent + Antioxidant lipid-lowering agent Phosphodiesterase-3 (cilostazol); Antioxidant mechanism (probucol) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Cilostazol+Probucol (Cilostazol+Probucol) — Otsuka Beijing Research Institute. Cilostazol inhibits phosphodiesterase-3 to increase cAMP and promote vasodilation and antiplatelet effects, while probucol acts as an antioxidant to reduce lipid peroxidation and improve lipid profiles.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cilostazol+Probucol TARGET	Cilostazol+Probucol	Otsuka Beijing Research Institute	marketed	Antiplatelet agent + Antioxidant lipid-lowering agent	Phosphodiesterase-3 (cilostazol); Antioxidant mechanism (probucol)
Cilostazol + Probucol group	Cilostazol + Probucol group	Otsuka Beijing Research Institute	marketed	Antiplatelet agent + Antioxidant lipid-lowering agent	Phosphodiesterase-3 (cilostazol); LDL oxidation pathway (probucol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent + Antioxidant lipid-lowering agent class)

Otsuka Beijing Research Institute · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cilostazol+Probucol — Competitive Intelligence Brief. https://druglandscape.com/ci/cilostazol-probucol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing